Get the Stockscreener App
0.3468
0.81%
0.0028
Pre-market:
.35
0.0032
+0.92%
Azitra Inc stock is traded at $0.3468, with a volume of 273.72K.
It is up +0.81% in the last 24 hours and down -12.86% over the past month.
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
See More
Previous Close:
$0.344
Open:
$0.357
24h Volume:
273.72K
Relative Volume:
0.04
Market Cap:
$5.19M
Revenue:
$1.27M
Net Income/Loss:
$-11.28M
P/E Ratio:
-0.0154
EPS:
-22.4496
Net Cash Flow:
$-10.46M
1W Performance:
+5.09%
1M Performance:
-12.86%
6M Performance:
-40.21%
1Y Performance:
+47.57%
1-Day Range:
$0.3453
$0.37
1-Week Range:
$0.33
$0.37
52-Week Range:
$0.0922
$12.00
Azitra Inc Stock (AZTR) Company Profile
Name
Azitra Inc
Sector
Industry
Phone
203 646 6446
Address
21 Business Park Drive, Branford
Compare AZTR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZTR
Azitra Inc
|
0.3468 | 5.19M | 1.27M | -11.28M | -10.46M | -22.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Azitra Inc Stock (AZTR) Latest News
Azitra (AZTR) Expected to Announce Quarterly Earnings on Friday - Defense World
Azitra to Present at Microbiome Times Partnering Forum - PR Newswire
AZTR: Netherton Topline Expected by Year-End - MSN
Azitra, Inc. (NYSEAMERICAN:AZTR) Short Interest Up 144.1% in February - Defense World
Azitra, Inc. Announces Full Year 2024 Financial Results and Provides Business Updates - Citizentribune
Azitra, Inc. Announces FY 2024 Financial Results and Business Updates - Defense World
Maxim Group cuts Azitra stock price target to $2 from $3, retains Buy rating - Investing.com
Maxim Group cuts Azitra stock price target to $2 from $3, retains Buy rating By Investing.com - Investing.com South Africa
Volcon, Inc. and GlucoTrack, Inc. See Massive Gains, While Omega Therapeutics and Universe Pharmaceuticals Struggle - HPBL
Monitoring Azitra Inc (AZTR) after recent insider movements - Knox Daily
AZTR’s price-to-free cash flow ratio: How it affects investment decisions - US Post News
Azitra Inc (AZTR) looking to reclaim success with recent performance - SETE News
Azitra (NYSEAMERICAN: AZTR) Closes Offering and Enters Into Agreement with Investors - Defense World
Azitra Inc. Enters into Placement Agency Agreement with Maxim Group LLC - Defense World
Certain Options of Azitra, Inc. are subject to a Lock-Up Agreement Ending on 8-FEB-2025. - Marketscreener.com
Azitra Inc Stock (AZTR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Cap:
|
Volume (24h):